Literature DB >> 23313958

Low-dose dobutamine adds incremental value to late gadolinium enhancement cardiac magnetic resonance in the prediction of adverse remodelling following acute myocardial infarction.

Anne E Scott1, Scott I K Semple, Thomas W Redpath, Graham S Hillis.   

Abstract

AIMS: To examine the relative and combined value of late gadolinium enhancement (LGE) and low-dose dobutamine (LDD) cardiac magnetic resonance (CMR) to predict 'adverse remodelling' (AR) following acute myocardial infarction (AMI). METHODS AND
RESULTS: Forty-five patients with AMI were recruited. CMR was performed 2-4 days after presentation and at 6 months. Ventricular wall motion and volume were recorded at rest and following dobutamine infusion. Measures of first pass perfusion, persistent microvascular obstruction (PMO), and LGE were obtained following contrast administration. Quantitation was performed using the MEDIS 6.2 software. Regression analysis was employed to determine the univariables and multivariate models most predictive of AR at 6 months. The incremental and relative value of LDD over LGE was investigated. The most predictive univariable was 'volume of PMO' (r = 0.51, r2 = 0.26, P < 0.001). The optimal 'combined' multivariate model, utilizing data from all components, was highly predictive of AR (r = 0.82, r2 = 0.67, P < 0.001). The optimal model using parameters only from the LGE component also predicted remodelling (r = 0.65, r2 = 42.0, P = 0.001) but with less accuracy. In contrast, the optimal model using variables from the LDD component alone predicted remodelling with a similar accuracy to the optimal combined model (r = 0.82, r2 = 0.67, P < 0.001).
CONCLUSION: A comprehensive CMR examination accurately predicts AR following AMI. LDD is superior to LGE CMR in this respect. These data suggest that LDD not only adds incremental value to LGE in the prediction of remodelling post-AMI but also may be utilized alone with the same predictive power.

Entities:  

Keywords:  Adverse remodelling; Cardiac magnetic resonance; Late gadolinium enhancement; Low-dose dobutamine magnetic resonance; Myocardial infarction; Viability

Mesh:

Substances:

Year:  2013        PMID: 23313958      PMCID: PMC3738097          DOI: 10.1093/ehjci/jes320

Source DB:  PubMed          Journal:  Eur Heart J Cardiovasc Imaging        ISSN: 2047-2404            Impact factor:   6.875


  25 in total

Review 1.  Standardized myocardial segmentation and nomenclature for tomographic imaging of the heart. A statement for healthcare professionals from the Cardiac Imaging Committee of the Council on Clinical Cardiology of the American Heart Association.

Authors:  Manuel D Cerqueira; Neil J Weissman; Vasken Dilsizian; Alice K Jacobs; Sanjiv Kaul; Warren K Laskey; Dudley J Pennell; John A Rumberger; Thomas Ryan; Mario S Verani
Journal:  Circulation       Date:  2002-01-29       Impact factor: 29.690

2.  Infarct zone viability influences ventricular remodelling after late recanalisation of an occluded infarct related artery.

Authors:  N G Bellenger; Z Yousef; K Rajappan; M S Marber; D J Pennell
Journal:  Heart       Date:  2005-04       Impact factor: 5.994

3.  Influence of infarct-zone viability on left ventricular remodeling after acute myocardial infarction.

Authors:  L Bolognese; G Cerisano; P Buonamici; A Santini; G M Santoro; D Antoniucci; P F Fazzini
Journal:  Circulation       Date:  1997-11-18       Impact factor: 29.690

4.  Influence of transmurality, infarct size, and severe microvascular obstruction on left ventricular remodeling and function after primary coronary angioplasty.

Authors:  Giuseppe Tarantini; Renato Razzolini; Luisa Cacciavillani; Claudio Bilato; Cristiano Sarais; Francesco Corbetti; Martina Perazzolo Marra; Massimo Napodano; Angelo Ramondo; Sabino Iliceto
Journal:  Am J Cardiol       Date:  2006-08-28       Impact factor: 2.778

5.  Myocardial 11C-diacylglycerol accumulation and left ventricular remodeling in patients after myocardial infarction.

Authors:  Hiroki Otani; Yutaka Kagaya; Yoshio Imahori; Satoshi Yasuda; Ryo Fujii; Masanobu Chida; Shigeto Namiuchi; Morihiko Takeda; Masahito Sakuma; Jun Watanabe; Tatsuo Ido; Hiroshi Nonogi; Kunio Shirato
Journal:  J Nucl Med       Date:  2005-04       Impact factor: 10.057

6.  Comparison of the usefulness of Doppler-derived deceleration time versus plasma brain natriuretic peptide to predict left ventricular remodeling after mechanical revascularization in patients with ST-elevation acute myocardial infarction and left ventricular systolic dysfunction.

Authors:  Giampaolo Cerisano; Paolo Domenico Pucci; Renato Valenti; Vieri Boddi; Angela Migliorini; Maria Silvia Tommasi; Silvia Raspanti; Guido Parodi; David Antoniucci
Journal:  Am J Cardiol       Date:  2005-04-15       Impact factor: 2.778

7.  Ultrasonic tissue characterization predicts left ventricular remodeling in patients with acute anterior myocardial infarction after primary coronary angioplasty.

Authors:  Yoshikazu Ohara; Yoshikazu Hiasa; Shinobu Hosokawa; Naoki Suzuki; Takefumi Takahashi; Koichi Kishi; Ryuji Ohtani
Journal:  J Am Soc Echocardiogr       Date:  2005-06       Impact factor: 5.251

Review 8.  Gadolinium-contrast toxicity in patients with kidney disease: nephrotoxicity and nephrogenic systemic fibrosis.

Authors:  Mark A Perazella
Journal:  Curr Drug Saf       Date:  2008-01

9.  Usefulness of intravenous myocardial contrast echoardiography in the early left ventricular remodeling in acute myocardial infarction.

Authors:  Giovanna Mengozzi; Roberta Rossini; Caterina Palagi; Giuseppe Musumeci; Anna Petronio; Ugo Limbruno; Paolo Caravelli; Vitantonio Di Bello; Mario Mariani
Journal:  Am J Cardiol       Date:  2002-10-01       Impact factor: 2.778

10.  Pressure-derived collateral flow index: a strong predictor of late left ventricular remodeling after thrombolysis for acute myocardial infarction.

Authors:  Murat Sezer; Yilmaz Nisanci; Berrin Umman; Sabahattin Umman; Irem Okcular; Ayhan Olcay; Ahmet Bilge; Mustafa Ozcan; Mehmet Meric
Journal:  Coron Artery Dis       Date:  2006-03       Impact factor: 1.439

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.